

### REMARKS

There are eleven (11) pending claims in this application. Applicant submits concurrently herewith an RCE in connection with this Preliminary Amendment. Claims 1-5 have been amended to overcome the rejections in the Office Action dated September 29, 2003. Claim 9 has been previously presented. Applicant cancels claims 6-8 and 10-11 without prejudice. No new matter has been introduced by the claim amendments and the amended claims are fully supported by the disclosure. For example, direct peptide interception therapy is fully disclosed in the specification (page 15, line 23 to page 16, line 22).

New claims 12-14 have been introduced via this Preliminary Amendment and they recite preferred embodiments of the present invention pertinent to the direct peptide interception therapy. Applicant believes that all the pending claims are free of prior art and patentable, and allowance of these claims is respectfully requested. The Examiner can reach the undersigned at (212) 908-6018 when he takes this application up for further action.

Respectfully submitted,  
KENYON & KENYON

Dated: March 29, 2004

By: \_\_\_\_\_

Siu K. Lo

Reg. No. 46,877

One Broadway  
New York, NY 10004  
Tel.: (212) 908-6018  
Fax: (212) 425-5288

617685v2